The common shares are dual-listed on the NYSE American and Cboe Canada

Davis Polk advised the placement agents in connection with a $175 million dual-listed U.S. and Canadian registered direct offering of 22,277,750 common shares of Cybin Inc., in lieu of common shares to certain investors, pre-funded warrants to purchase 4,605,500 common shares and warrants to purchase 9,409,138 common shares. Cybin’s shares are listed on the NYSE American and Cboe Canada under the symbol “CYBN.”

Cybin, headquartered in Toronto, Ontario, is a breakthrough Phase 3 clinical-stage neuropsychiatry company working to revolutionize the mental health treatment landscape through the introduction of novel drugs that provide effective and durable results. Cybin operates in Canada, the United States, the United Kingdom and Ireland.

The Davis Polk capital markets team included partner Yasin Keshvargar and associates Raphaelle Desaleux and Kerim K. Aksoy. The tax team included counsel Dustin Plotnick and associate Valentin Van de Walle. The intellectual property team included partner David R. Bauer and associate Hannah Coleman. Members of the Davis Polk team are based in the New York and Northern California offices.

Copy link to share post